RU 58841Androgen receptor antagonist CAS# 154992-24-2 |
- MDV3100 (Enzalutamide)
Catalog No.:BCC1268
CAS No.:915087-33-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 154992-24-2 | SDF | Download SDF |
| PubChem ID | 132981 | Appearance | Powder |
| Formula | C17H18F3N3O3 | M.Wt | 369.35 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (270.75 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile | ||
| SMILES | CC1(C(=O)N(C(=O)N1CCCCO)C2=CC(=C(C=C2)C#N)C(F)(F)F)C | ||
| Standard InChIKey | ARBYGDBJECGMGA-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H18F3N3O3/c1-16(2)14(25)23(15(26)22(16)7-3-4-8-24)12-6-5-11(10-21)13(9-12)17(18,19)20/h5-6,9,24H,3-4,7-8H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
RU 58841 Dilution Calculator
RU 58841 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7075 mL | 13.5373 mL | 27.0746 mL | 54.1492 mL | 67.6865 mL |
| 5 mM | 0.5415 mL | 2.7075 mL | 5.4149 mL | 10.8298 mL | 13.5373 mL |
| 10 mM | 0.2707 mL | 1.3537 mL | 2.7075 mL | 5.4149 mL | 6.7686 mL |
| 50 mM | 0.0541 mL | 0.2707 mL | 0.5415 mL | 1.083 mL | 1.3537 mL |
| 100 mM | 0.0271 mL | 0.1354 mL | 0.2707 mL | 0.5415 mL | 0.6769 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
A specific androgen receptor antagonist or anti-androgen; RU 58841 has a dramatic effect on hair regrowth.
- Erysenegalensein E
Catalog No.:BCN3979
CAS No.:154992-17-3
- BAY-u 9773
Catalog No.:BCC7576
CAS No.:154978-38-8
- LL 37
Catalog No.:BCC8027
CAS No.:154947-66-7
- Kaempferol 3,7,4'-trimethylether
Catalog No.:BCN4087
CAS No.:15486-34-7
- 3,5-Dihydroxy-4',7-dimethoxyflavone
Catalog No.:BCN1691
CAS No.:15486-33-6
- Eleutheroside C
Catalog No.:BCN1690
CAS No.:15486-24-5
- 4-Acetoxycinnamic acid
Catalog No.:BCN5026
CAS No.:15486-19-8
- Cimiside E
Catalog No.:BCN7951
CAS No.:154822-57-8
- 2-(2'-Hydroxytetracosanoylamino)-octadecane-1,3,4-triol
Catalog No.:BCN1555
CAS No.:154801-30-6
- 3-Methoxymollugin
Catalog No.:BCN7164
CAS No.:154706-44-2
- Tezampanel
Catalog No.:BCC1993
CAS No.:154652-83-2
- Efavirenz
Catalog No.:BCC4135
CAS No.:154598-52-4
- Methscopolamine
Catalog No.:BCC4577
CAS No.:155-41-9
- Rhaponiticin
Catalog No.:BCN5392
CAS No.:155-58-8
- Ac-Arg-OH.2H2O
Catalog No.:BCC2855
CAS No.:155-84-0
- Pancuronium dibromide
Catalog No.:BCC4578
CAS No.:15500-66-0
- Isatidine
Catalog No.:BCN2120
CAS No.:15503-86-3
- Usaramine
Catalog No.:BCN2121
CAS No.:15503-87-4
- 4-Hydroxy-3-(3-methyl-2-butenoyl)-5-(3-methyl-2-butenyl)benzoic acid
Catalog No.:BCN1554
CAS No.:155051-85-7
- N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide
Catalog No.:BCC6784
CAS No.:155054-42-5
- SM-21 maleate
Catalog No.:BCC6780
CAS No.:155059-42-0
- 24,25-Dihydroxycycloartan-3-one
Catalog No.:BCN1692
CAS No.:155060-48-3
- 11-Deoxyalisol B
Catalog No.:BCN3359
CAS No.:155073-73-7
- 6-ethyl-3-methyl-4-oxo-4H-pyran-2-carboxylic acid
Catalog No.:BCC8270
CAS No.:1551-49-1
RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism.[Pubmed:8136306]
J Steroid Biochem Mol Biol. 1994 Jan;48(1):55-60.
A new topically active non-steroidal antiandrogen, RU 58841 has been synthesized. It displays high affinity for the hamster prostate and flank organ (F.O.) androgen receptors. In vivo, when topically applied, it exerts a potent dose-dependent regression of F.O. area at a dose as low as 1 microgram/animal while being devoid of antiandrogenic activity on deep accessory sex organs and of any effect on testosterone level up to 100 micrograms/animal. In the same species, after subcutaneous administration, it induces at the dose of 300 micrograms/animal, a small decrease in F.O. area equivalent to that of 1 microgram applied topically and a weak systemic activity. In intact rats, no effects were observed up to 1 microgram/animal whatever the route of administration. These results suggest that RU 58841 might useful for the topical treatment of androgen-dependent skin disorders such as acne, androgenetic alopecia and hirsutism.
RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia.[Pubmed:15700772]
Pharmazie. 2005 Jan;60(1):8-12.
Acne and androgenetic alopecia are linked to androgen effects and therefore should improve following topical application of antiandrogens. We present a new antiandrogen prodrug, RU 58841-myristate (RUM) for topical therapy. Almost devoid of affinity to the androgen receptor, as derived from investigations in the mouse fibroblast cell line 29 +/GR +, RUM is rapidly metabolised to the potent antiandrogen RU 58841 by cultured human foreskin fibroblasts and keratinocytes, male occipital scalp skin dermal papilla cells, and by cells of the sebaceous gland cell line SZ95. In order to improve a specific targeting of the hair follicle, RUM was loaded on solid lipid nanoparticles (SLN), which are already known to support dermal targeting effects. Physically stable RUM loaded SLN were produced by hot homogenization. Penetration/permeation studies carried out using the Franz diffusion cell proved only negligible permeation of reconstructed epidermis and excised porcine skin within 6 h, implying a more topical action of the drug. Targeting to the hair follicle using SLN was visualised by fluorescence microscopy, following the application of Nile Red labelled SLN to human scalp skin. Transmission electron microscopy (TEM) allowed to detect intact silver labelled SLN in porcine hair follicles of preparations applied to the skin for 24 h. RUM loaded SLN should be considered for topical antiandrogen therapy of acne and androgenetic alopecia.
Local inhibition of sebaceous gland growth by topically applied RU 58841.[Pubmed:7625751]
Ann N Y Acad Sci. 1995 Jun 12;761:56-65.
The biological activity of a series of nonsteroidal, pure androgen receptor inhibitors was compared using the Syrian hamster ear skin sebaceous gland model. RU 58841, RU 56187, RU 38882 and cyproterone acetate were applied topically for 4 weeks on the ventral ear pinna of sexually mature male Syrian hamsters. Their order of efficacy was as follows: RU 58841 > RU 56187 > RU 38882 > cyproterone acetate. Maximal reduction of 60% in the size of the sebaceous glands was observed in hamsters treated with RU 58841 at a dose of 10 micrograms per day. This degree of inhibition occurred without any systemic side effects as shown by the absence of inhibition on the contralateral untreated ear pinna. Longer treatment did not produce greater inhibition since extending the treatment period from 4 weeks to 12 weeks showed similar data. The effect of RU 58841 was reversible since the inhibited sebaceous glands returned to normal size within 4 weeks after the cessation of the topical applications. The potent localized inhibition of sebaceous glands by RU 58841 demonstrates the excellent potential of this compound as a topical drug for the treatment of acne and other androgen-mediated disorders.
